CORONA, CA / ACCESSWIRE / August 17, 2020 / ADOMANI, Inc. (OTCQB:ADOM) a provider of new zero-emission, purpose-built electric vehicles and drivetrain solutions, is pleased to announce that it has entered into a strategic alliance with the San Diego Energy District (SDED) in order to accelerate the realization of a clean energy economy. SDED's mission is to move toward a clean energy economy through achieving 100% renewable, locally-generated electricity throughout California, initially focusing on the San Diego and Southern California areas. SDED and ADOMANI also intend to evaluate sponsorships, zero-emission vehicle demonstrations, pilot deployments and other collaborative opportunities. A goal of the alliance is for SDED to provide direct introductions to forward-thinking, environmentally conscious businesses that utilize commercial fleet vehicles in their operations that could be replaced with ADOMANI zero-emission electric alternatives, and build brand awareness in the global green community SDED serves and advises. ADOMANI will provide vehicles in person or via video conferencing for events and demonstrations in California communities where SDED identifies opportunities.

"This is an exciting development for ADOMANI, as we believe we can help SDED meet their goals by getting our cutting-edge, technologically-advanced zero-emission all-electric products in service through their introductions and branding assistance, while benefiting our stockholders as well" said Jim Reynolds, President and CEO of ADOMANI. "In addition, we will help fleets that want to lower their TCO (total costs of ownership) and related operating costs."

"The decision of the California Air Resources Board to accelerate the adoption of electric commercial vehicles implies that commercial vehicle operators should become knowledgeable of the choices available to them like ADOMANI" stated Lane Sharman, Executive Director of the San Diego Energy District. "We intend through our webinars, conferences and pilots to demonstrate that ADOMANI is an electric vehicle supply choice that every buyer should consider in order to make an informed decision."

About ADOMANI®

ADOMANI, Inc. is a provider of new zero-emission electric vehicles and is a provider of zero-emission electric drivetrain systems for integration in medium to heavy-duty commercial fleet vehicles, as well as re-power conversion kits for the replacement of drivetrain systems in combustion-powered vehicles. ADOMANI's zero-emission electric vehicles are focused on reducing the total cost of vehicle ownership and help fleet operators unlock the benefits of green technology and address the challenges of traditional fuel price cost instability and local, state and federal environmental regulatory compliance. For more information visit www.ADOMANIelectric.com

About San Diego Energy District

The San Diego Energy District exists to speed the 100% clean electricity future, primarily through creation of Community Choice energy programs, which they believe to be the quickest to implement and the most affordable means of achieving their goals. SDED believes that the current system of regulated monopoly utilities is outdated and is slow to respond to smart energy use and decentralized generation. They believe the optimal partnership is one between Community Choice, where people select the generation provider or source, and the utility, who still gets paid to operate the wires efficiently. For more information visit http://www.sandiegoenergydistrict.org/

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that relate to future plans, events, financial results, prospects or performance are forward-looking statements. While they are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in reports filed by ADOMANI with the Securities and Exchange Commission, all of which are available online at www.sec.gov. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "planned," "expects," "believes," "strategy," "opportunity," "anticipates," "outlook," "designed" and similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, ADOMANI undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Investor Relations Contacts:

ADOMANI, Inc.

Kevin Kanning, VP Investor Relations
Telephone: (650) 533-7629
Email: kevin.k@ADOMANIelectric.com

Michael K. Menerey, Chief Financial Officer
Telephone: (951) 407-9860 ext. 205
Email: mike.m@ADOMANIelectric.com

Renmark Financial Communications, Inc.

Joshua Lavers
Telephone: (416) 644-2020, ext. 3409 or (514) 939-3989
Email: jlavers@renmarkfinancial.com

SOURCE: ADOMANI, Inc.

ReleaseID: 601816

Including Highlights from BioLargo's Second Quarterly Report of 2020

WESTMINSTER, CA / ACCESSWIRE / August 17, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, provided an overview today on recent highlights for its business units. This overview coincides with the filing of BioLargo's 10-Q Quarterly Report with the SEC for the period ended June 30, 2020 (www.biolargo.com/sec-filings).

Highlights include:

Clyra Medical Technologies launched Clyraguard Personal Protection Spray, a safe, effective, FDA-registered disinfectant designed to decontaminate medical devices such as face masks and other personal protection equipment (PPE). The product has been met with great enthusiasm, and sales are ramping up.
As part of a multi-phase product roll-out plan, Clyra secured a $1 million inventory line of credit and formed relationships with three contract-manufacturers that are actively producing Clyraguard. Distribution partners for Clyraguard are just beginning sales activities, having recently received their initial inventory. Given the sales achieved in recent weeks and volume of orders in process, the company expects to report substantial revenue increases from product sales in the third quarter of 2020. Company management reports that its current manufacturing resources are capable of producing up to one million Clyraguard units per month before it would need to expand with additional contract manufacturers.
BioLargo Water will soon start the first commercial project for its AOS water treatment system, which will be funded by government grants and its client and is expected to generate more than $500,000 USD in revenue over the life of the project.
BioLargo Engineering manufactured a medium-scale demonstration pilot prototype of the BioLargo AEC, the company's per- and polyfluoroalkyl substance (PFAS) water treatment technology. The company will start two field demonstration pilots of the AEC in the coming months.
ONM Environmental (formerly Odor-No-More, Inc.) is restarting multiple capital projects that were on hold due to the COVID-19 pandemic, and was recently notified of an award for a project valued at approximately $130,000.
BioLargo's company-wide revenue for the three and six months ended June 30, 2020 was $418,000 and $856,000, which is a 2% decrease and 8% increase over the same periods in 2019. Sales at the company's operating divisions decreased at the start of the pandemic, but are now rebounding.
BioLargo continues to strengthen its balance sheet as it converts approximately $3,500,000 of debt to equity since December 31, 2019 through August 2020.

BioLargo President & CEO Dennis P. Calvert commented, "In the COVID-19 pandemic, we demonstrated our resiliency as we managed to maintain stable operations, cleaned up our balance sheet, developed and launched a brand new product (Clyraguard) to help frontline workers battling the pandemic, and made multiple adaptations to be a strong solutions provider in a global pandemic. We're now seeing our hard work translate to increasing sales. We have a number of new relationships with distribution partners that we plan to share more information about as they begin selling Clyraguard. While the commercial opportunity for Clyraguard is immediate and has the potential for significant commercial success, the rest of our technology portfolio continues to advance, and we remain confident about their future."

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective against viruses and bacteria, and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

SOURCE: BioLargo, Inc.

ReleaseID: 601948

DENVER, CO and PERTH, AUSTRALIA / August 17, 2020 / Samson Oil & Gas Limited ("Samson" or the "Company") advises that, effective at 5:00 PM Eastern Time on Friday, August 14, 2020, the Company's Level I American Depositary Receipt Program was terminated. Upon termination, holders of Samson's American Depositary Shares ("ADSs") may surrender their ADSs for delivery of the underlying ordinary shares of the Company. Each ADS represents twenty (20) ordinary shares. There is currently no active trading market for the ordinary shares, which previously traded on the Australian Stock Exchange, and the ordinary shares are not eligible for listing on a national securities exchange in the United States.

The Company supports the development of an over the counter trading market for its ordinary shares in the United States to replace the existing over the counter trading market for the ADSs. The Company has obtained an ISIN (AU000000SSN0) and CUSIP number (Q82577 125) for the ordinary shares. Accordingly, U.S. broker-dealers wishing to effect trades of ordinary shares may file a Form 211 with FINRA to have a trading symbol issued for the ordinary shares of the Company.

SAMSON OIL & GAS LIMITED

For further information please

contact, Tristan Farel, CEO on

303 524 3366 (US office)

TRISTAN FAREL
Managing Director

Statements made in this press release that are not historical facts may be forward looking statements, including but not limited to statements using words like "may", "believe", "expect", "anticipate", "should" or "will." Actual results may differ materially from those projected in any forward-looking statement. There are a number of important factors that could cause actual results to differ materially from those anticipated or estimated by any forward looking information, including the risk that an over the counter market for the ordinary shares will never develop in the United States. A description of the risks and uncertainties that are generally attendant to Samson and its industry, as well as other factors that could affect Samson's financial results, are included in the prospectus and prospectus supplement for its recent Rights Offering as well as the Company's report to the U.S. Securities and Exchange Commission on Form 10-K, which are available at www.sec.gov/edgar/searchedgar/webusers.htm.

SOURCE: Samson Oil & Gas Limited

ReleaseID: 601993

TORONTO, ON / ACCESSWIRE / August 17, 2020 / California Gold Mining Inc. ("California Gold" or "CGM" or the "Company") (CSE:CGM)(OTCQX:CFGMF) is pleased to announce the realization of revenue from the sale of the first tranche of CBD Isolate produced from its wholly-owned hemp biomass, as per the sale agreement announced on January 29, 2020.

Details of the sale are as follows:

Total quantity of CBD Isolate sold in this first tranche is 71 kilograms;

Total revenue generated is US$248,500;

Sale price is US$3,500 per kilogram of CBD Isolate;

Cost of Goods Sold associated with the production and sale of CBD Isolate is approximately US$2,450 per kilogram; and

Gross Margin from the sale of this first tranche is 30%.

CGM's current inventory of bulk hemp-CBD products equates to over 1,250 kilograms of CBD Isolate. Following the sale of this initial tranche, the Company's management expects to complete sales of successive tranches on a regular basis until the entire inventory of CBD Isolate is sold.

California Gold's President and CEO, Mr. Vishal Gupta stated, "For a junior company that has never realized any meaningful revenue in its entire history, the completion of this first sale is a truly extraordinary feat. What makes today's announcement an even more impressive achievement is that the Company was able to generate a Gross Margin of 30% on this first sale despite the devastating price compression that the US hemp-CBD industry has been reeling from since last December."

Mr. Gupta goes on to say, "We have had a significant delay in achieving our sales objectives, primarily due to the onset of the global COVID-19 pandemic in March. Our toll-processing partners in North Carolina suffered crippling restrictions to their extraction and isolation operations as a result of the continually high COVID-19 infection rates in the state. Some of those restrictions were eased recently, which allowed the CBD Isolate production to re-start at their facility, culminating in the completion of our first sale. We plan to complete sales of additional tranches of CBD Isolate on a regular basis going forward."

Management expects to complete the sale of a second tranche of CBD Isolate in the next 15 days. The Company's Board of Directors continues to investigate the economics of purchasing additional batches of hemp biomass in order to produce and eventually sell additional refined products once the sale of the current inventory of refined products is complete.

About California Gold Mining Inc.

California Gold Mining Inc. is focused on continued development of a high-quality gold resource on its 100%-owned Fremont property in Mariposa County, California. The Fremont property consists of an entirely private and patented land package totaling 3,351 acres of historically producing gold mines, with a state highway, PG&E electric substation and abundant water present on the property itself. The Fremont property lies within California's prolific Mother Lode Gold Belt that has produced over 50 million ounces of gold. The Company purchased the Fremont property in March 2013.

The Company also has an outdoor, high-CBD industrial hemp biomass cultivation operation on its Grove Road Farm property totaling 82 acres of agricultural farmland in Kendall County, Illinois. The Company plans to use a portion of cash flow from its hemp biomass and hemp seed operations to continue development of its gold business, with minimal dilution for shareholders.

The Company's technical report in respect of the Fremont Property prepared pursuant to National Instrument 43-101 is available on SEDAR at www.sedar.com and on the Company's website at www.caligold.ca.

CAUTION REGARDING FORWARD-LOOKING INFORMATION

This news release of California Gold contains statements that constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause California Gold's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements in this document include statements regarding (i) potential sales of CBD Isolate and the timing of such sales, (ii) the ability of the Company to achieve similar gross margin on future sales of CBD Isolate to the gross margin received on the sale disclosed in this press release and (iii) the Company's plans to acquire additional hemp biomass. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated by such statements and could materially affect the Company's results of operations. Readers are cautioned not to place undue reliance on forward looking statements in this press release. California Gold does not undertake any obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change, unless otherwise required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Vishal Gupta, President & CEO
Tel.: 647-977-9267 x333 | Website: www.caligold.ca

SOURCE: California Gold Mining Inc.

ReleaseID: 601994

Players in the bulk material handling systems market are focusing on applications in essential sectors including food & beverage, animal feed, agriculture, and minerals for the duration of the outbreak.

DUBAI, UAE / ACCESSWIRE / August 17, 2020 / The coronavirus pandemic has had a substantial effect on the bulk material handlings systems industry. Nationwide lockdown measures have restricted industrial operations in multiple sectors. Industries reliant on supplies from Asia in particular have been hit hard. Consequently, the bulk material handling systems market is likely to go through a short term downturn.

"Bulk material handling is a key intermediary step in manufacturing and processing sectors. While these systems do not contribute directly to the end product, applications bolster efficacy in material management, handling, storage, and the transportation of materials through efficient circulation, aiding the growth of demand in myriad verticals," says the FMI analyst.

For more insights into the Market, Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-672

Bulk Material Handling System – Primary Takeaways

Automated guided vehicles are key contributors to revenue for optimization of labor, and logistics costs.
Material tracking software and automation sensors are expected to gain major traction among end users to bolster throughput.
Europe will play a major role in the development of the bulk material handling systems owing to major investments into industry 4.0, robotics, and IoT.

Bulk Material Handling System – Growth Factors

Consistent growth in industrial infrastructure investments is a key driving factor for bulk material handling systems.
Investments and adoption of Industry 4.0 operation models are contributing to demand.

Bulk Material Handling System – Major Constraints

High initial investments and operational costs hurt sales prospects for bulk material handling systems.
Advancements in material and technology have reduced replacement demand, limiting sales.

The Projected Impact of Coronavirus

The coronavirus pandemic is anticipated to generate substantial supply chain disruptions for the bulk material handling systems industry owing to major nationwide lockdowns, particularly in Asian supplier countries. In addition, concerns over worker health in multiple industrial verticals has hurt demand for bulk material handling systems. Improvements in automation capabilities will become critical for market players in the near future.

For information on the Research Approach used in the Report, Request Methodology@ https://www.futuremarketinsights.com/askus/rep-gb-672

Competition Landscape

The bulk material handling systems market comprises players including but not limited to Motridal S.p.A., FL Smidth, Beumer Group, ThyssenKrupp, Satake Corp, Techint Group, Schneck Process Holding GmbH, Hitachi Construction Machinery Co., L&H Industrial, Liebherr Group, and Metso Corp.

Players in the bulk materials handling systems market are bolstering investments towards the expansion and development of facilities to keep up with changing requirements of major end user industries.

For instance, ASGCO has announced the transition and expansion of operations from Allentown to Nazareth in Pennsylvania which will include the production of bulk material handling systems. Further, Flexco Europe is relocating to a larger facility in Rosenfeld, Germany including development of bulk material handling equipment. Also, Fluor Bulk Materials Handling has opened a new subsidiary Virta Inc. for minerals and metallurgy materials handling.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/request-special-price/rep-gb-672

More About the Study

The FMI study provides detailed insights on the bulk material handling systems market. The market is broken down in terms of equipment (stacker, stacker cum reclaimer, band conveyor,bucket wheel excavator, stripping shovel, rope shovel, bucket excavator, and ship loader & unloader), and application (mining, packaging, construction, manufacturing, and seaports & cargo terminals) across five key regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Explore FMI's Coverage of the Industrial Automation & Equipment Industry

Magnetic Separator Market: Find insights on the magnetic separator market with segment analysis, statistics, influencing factors, players and strategies adopted by market players for a 10-year forecast period.

Produced Water Treatment Systems Market: FMI's report on the produced water treatment systems market offers details on the market between 2019 -2029. The study covers influencers, revenue sources, market leaders, and strategies.

Lead Acid Battery Market: Get an in-depth analysis on the lead acid batery market with insights on growth levers, opportunities, policies, restraints, regional markets and market leaders.

About Future Market Insights

Expert analysis, actionable insights, and strategic recommendations of the experienced research team at FMI helps clients from across the globe with their unique business intelligence requirements. With a repository of more than thousand reports and 1 million+ data points, the team has studied the industrial automation & equipment sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

Contact

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com

Report: https://www.futuremarketinsights.com/reports/bulk-material-handling-system-market
Press Release Source: https://www.futuremarketinsights.com/press-release/bulk-material-handling-system-market

SOURCE: Future Market Insights

ReleaseID: 601985

MONTREAL, QC / ACCESSWIRE / August 17, 2020 / Mondias Natural Products Inc. (TSXV:NHP) (the "Company" or "Mondias") specializing in evidence-based natural products for the healthcare and bio-agriculture markets and Tetra Bio-Pharma Inc. ("Tetra"), (TSX-V:TBP) (OTCQB:TBPMF), a biopharmaceutical leader in the discovery and development of cannabinoid-derived therapeutics are pleased to announce they are entering into Definitive Agreement for the purchase of Lumiera Health Innovation Inc. ("Lumiera") as previously announced on July 23, 2020. The agreement will be submitted to Mondias Annual General and Special Meeting of Shareholders to be held September 14, 2020. If approved, the expected closing date for the transaction will be on or around September 30, 2020.

In connection with the Definitive Agreement , the Company will, among other:

Redeem or convert all of its outstanding convertible notes issued in February 2020 at a redemption price equal to the principal amount owing pursuant to such notes plus all applicable and unpaid interest thereon up to but excluding the date of the transaction; and
issue new common shares in exchange for all of the issued and outstanding shares of Lumiera Health Innovations Inc.; and
amalgamate its wholly owned subsidiary Laboratoire Holizen Inc. and Lumiera (following the share exchange),
The Company will undertake to change its name from "Mondias Natural Products Inc./Produits Naturel Mondias Inc." to "Lumiera Health Innovations Inc." because the new name better reflects and describes the business of the Corporation following the proposed transaction.

The Definitive Agreement is subject to the completion of an equity financing of a minimum of $1,000,000 by means of private placement by Mondias, of which $500,000 has to be completed concurrently with the closing of the transaction, as well as a $2,000,000 convertible debenture by Lumiera, which will be assumed by Mondias on closing of the transaction.

The proposed transaction was unanimously approved by the Mondias' and Tetra's board of directors (with Mr. Guy Chamberland abstaining, as he is a director and officer of Tetra as well as one of the shareholders of Mondias). In doing so, the Board of directors of the Company determined that the transaction is fair to the shareholders other than the interested parties, is in the best interest of the Company, and it authorized the submission of the Definitive Agreement and related transactions to the security holders for approval. The Board also unanimously agreed to recommend to the Company shareholders that they vote in favour of the proposed transaction.

Full details of the transaction and related transactions will be included in the Company's Management Information Circular which is expected to be mailed to security holders in August 2020.

Purpose and Business Reasons for the Transaction

The Board considered the historical and current information concerning Lumiera's business, financial condition, including Lumiera's operations, management and competitive position, the prospects of Lumiera and its product candidates, the nature of the industry generally, including financial projections of Lumiera under various scenarios and its short- and long-term strategic objectives and the related risks, and believe that the acquisition of Lumiera would create more value for Shareholders in the long-term.

The proposed transaction is highly complementary and further positions the Company for success, by adding new clinically proven solutions in natural health products and pain relief solution in larger addressable market (North America and worldwide). Lumiera also comes with an experienced team in pharmaceutical and natural products commercialization (manufacturing, sales & marketing, commercial operations) with products in commercialization phases assorted with an attractive products pipeline.

The proposed transaction will allow the Company to acquire the intellectual property rights owned by Lumiera in the fields of chronic pain and inflammation markets. The Board's belief, based in part on the judgment, advice and analysis of the Company's management with respect to the potential strategic, financial and operational benefits of the proposed transaction (which judgment, advice and analysis was informed in part by the business, technical, financial, accounting and legal due diligence investigation performed by the Company and the Company's legal advisors with respect to Lumiera), that Lumiera's product candidates represent a sizeable market opportunity, and may provide new health benefits for the population and returns for investors.

The Board also considered the experience of Lumiera's management, marketing and scientific teams. The proposed transaction would also allow the Company to gain complementary competencies by gaining new employees with core expertise in the natural product industry.

The Share Exchange

Pursuant to the Share Exchange Agreement, the Corporation has agreed to acquire all of the issued and outstanding shares in the capital of Lumiera for a purchase price of $1,280,000 million (the "Transaction Price"). The entire Transaction Price is payable through the issuance of 16,000,000 Common Shares at an issuance price equal to the closing price of the Common Shares on the TSXV on the day prior to the signature of the LOI, being $0.08 per Common Share.

Settlement of Debt

As a condition to the closing of the Proposed Transaction under the Definitive Agreement, the Company has agreed to enter into settlement agreements (the "Settlement Agreements") with all holders of the Company's (i) Class I preferred shares, (ii) Class E preferred shares, and (v) unsecured convertible debentures, as well as the holders of any outstanding (vi) Shareholder loan or (vii) owed director fees, to settle all amounts owing to them in consideration for the issuance of Common Shares of the Corporation, at an issuance price equal to the closing price of the Common Shares on the TSXV on the day prior to the signature of the LOI, being $0.08 per Common Share. All conversions pursuant to such Settlement Agreements shall have been completed prior to or at closing.

Board of Directors and Management of the Resulting Issuer

Under the terms of the definitive agreement, the board of directors of the resulting issuer will be comprised of 5 directors. A new management team will also be appointed. The following are the names and biographies of the proposed directors and officers:

Kevin Roland (Chief Executive Officer and Director)

Mr. Roland is the Chief Executive Officer of Lumiera Innovation Health Inc. since March 2020. He was Vice President & CMC (chemistry, manufacturing & control) for Better Life Pharma Inc. from 2019 to 2020. Prior to this, he was Director CMC for Canopy Growth Corporation Inc. From 2014 to 2018, he was respectively Vice President CMC and Strategic Innovation, Senior Director PET and Director New Product Development for Isologic Radiopharmaceutiques Novateurs. From 2010 to 2014 he was Radiochemist, Chemistry system owner. He holds a Bachelor's degree and a Master's degree in Chemistry Sciences from University of Mons, Belgium. He also follows the Intensive program EMMI (European Master's in molecular Imaging) from the University of Torino.

Mario Paradis, CPA, CA, ICD.D (Chief Financial Officer and Director)

Mr. Paradis is the Chief Financial Officer of the Corporation. He was Vice President and Chief Financial Officer of Neptune Wellness Solutions Inc. from August 2015 until November 2019 and of Acasti Pharma Inc. from August 2015 until August 2016. Between 2008 and 2015, Mr. Paradis was Vice President and Chief Financial Officer at Atrium Innovations Inc., a company operating in the natural product industry, which was acquired in 2014 by corporations backed by the Permira Funds in a transaction valued at over $1.1 billion. Prior to this, Mr. Paradis held roles of increasing authority at Aeterna Zentaris, most notably as Vice President Finance and Administration & Corporate Secretary. Mr. Paradis began his career at PricewaterhouseCoopers (PwC), where he successfully held senior positions primarily in audit and tax. Mr. Paradis is a member of the Canadian Chartered Professional Accountants (CPA) and also a member of the Institute of Corporate Director (ICD). He holds a Bachelor's degree in Business, with a specialty in Accounting, from Université du Québec at Trois-Rivières.

Kevin Cole (Director and Chairman of the Board)

Mr. Cole is President of True Leaf Pet since May 2019. From 2007 until 2019, he was respectively Vice President, Sales Strategy and Brand Marketing, Marketing Director and Portfolio Director at Mars Petcare. Prior to this, he was Brand Manager from 2004 to 2007 for GlaxoSmithKline Consumer Healthcare. He holds an honours Bachelor's degree in Business Administration from Wilfrid Laurier University.

Marie Bélanger (Director)

Mrs. Bélanger is a business development consultant and a professional coach since 2018. She is part of the Senior Business Advisor team at Inno-Centre, which specializes in advising small to medium-sized businesses in Canada. From 2013 until 2018, she was Manager, Sales and Telemarketing at Phytoderm Canada and from 2011 to 2013, she was Manager, Business Development Retail for Hygie Canada. Prior to this, she was Chief Operating Officer for Santé Naturelle (AG) Ltée from 2008 to 2009. From 1990 until 2005, Mrs. Bélanger held roles of increasing authority at Santé Naturelle (AG) Ltée, most notably as General Manager (DG). Mrs. Bélanger started her career with Procter and Gamble as a sales representative in 1985. Mrs. Bélanger holds a Bachelor's degree in Business with a speciality in finance, international relations from McGill University. She is also an Associate Certified Coach (ACC) and member of ICF (International Coach Federation).

Nathalie Nasseri (Director)

Mrs. Nasseri is the managing director and co-owner of Bleu Lavande Inc. since June 2015. From 2012 to 2015, she was Vice-President, Marketing North America for Bridor Inc. Between November 2005 until 2011, she was respectively Manager National Marketing and Vice President, National Marketing. Prior to this, she was brand manager at Molson from 2000 to 2005 and from 1993 to 2000, she was with different publicity agencies. Mrs. Nasseri holds a Bachelor's degree in Business and Marketing from the HEC school in Montreal and a minor in Antropology.

Conditions of Closing

Completion of the transaction will be subject to certain conditions, including:

the Company obtaining approval of the majority of the votes cast by the Company's shareholders, excluding Mr. Guy Chamberland's vote;
the Company obtaining the consent of TSX Venture in connection with the Definitive Agreement;
the Company redeeming all outstanding Series I and E Preferred Shares in accordance with their terms; and
neither the Company nor Lumiera having suffered a material adverse effect.

Concurrent Private Placement

The Company plans to complete a concurrent, non-brokered private placement of up to $1,000,000 at a minimum price of $0.065 per share, of which $500,000 has to be completed before the closing of the transaction. The Concurrent Financing will be completed through the issuance of Common Shares (or units comprised of Common Shares and warrants) at a price equal to the market price of the Common Shares on the TSXV at the time that the final terms of the Concurrent Financing are confirmed by the Board of the Company.

The intended proceeds of the private placement are for the further develop the Lumiera and Holizen product portfolio as well as for general corporate purposes. The shares to be issued pursuant to the private placement will be subject to statutory hold periods pursuant to applicable securities laws, expiring four months after the closing date.

About Mondias Natural Products Inc.

Mondias specializes in the commercialization and development of evidence-based botanical products for the healthcare, bio-agriculture, and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns, and golf courses and in urban gardens, nurseries, commercial greenhouses and to indoor cannabis growers, in collaboration with McGill's Faculty of Agricultural and Environmental Sciences. For more information, visit: www.mondias.ca

About Lumiera Health Innovation Inc.

Lumiera Health Innovation is a Canadian-based natural health product company, aiming to help improve people's lives by delivering innovative health products inspired by nature. The company is developing and commercializing a unique portfolio of products acting on the endocannabinoid system and providing innovative solutions for chronic pain and inflammation. As a pioneer in the health and pain management innovation space, the Lumiera brand is rooted in the core brand values of science, nature and compassion. Passionate about making people feel better, we deliver trustworthy and scientifically proven solutions that work with the body's own system. For more information visit www.lumiera.ca

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's or Tetra's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include the Company's and Tetra's inability to completed the Proposed Transaction, Tetra's ability to enter into a convertible debenture facility or other credit facility for aggregate gross proceeds of approximately $2 million, on terms satisfactory to Lumiera and Tetra, Company's inability to raise capital in the market to finance the development of the Lumiera natural health products, including the Holizen brand, and the new sleep aid product BazzicsTM, Company's inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company's research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise except as required by applicable securities legislation.

For more information:

Mondias Natural Products Inc.
Mario Paradis, CPA, CA
Chief Financial Officer
514-641-0181
mparadis@mondias.ca

Lumiera Health Innovation Inc.
Kevin Roland
Chief Executive Officer
514-893-2902
kroland@lumiera.ca

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:
Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net

Media Contact:
energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com

SOURCE: Tetra Bio-Pharma

ReleaseID: 601956

Record Revenues and Quarterly Growth of 43% Alongside Reduced Operating Expenses Leads to 70% Improvement in Operating Loss to $0.2 Million and Continued Margin Expansion

PHOENIX, AZ / ACCESSWIRE / August 17, 2020 / Item 9 Labs Corp. (OTCQB:INLB) ("Item 9 Labs" or the "Company"), a vertically integrated cannabis operator that produces premium products, announced today the Company's operating and financial results for the fiscal third quarter ended June 30, 2020.

Key Financial Highlights for Q3 FY 2020

Revenue increased 43% to $2.2 million over Q3 FY 2019
Operating loss decreased 70% to $0.2 million
Operating expenses as a percentage of revenue declined from 108% to 57%
Adjusted EBITDA loss declined 91% to $0.04 million

Management Commentary

"It has been an eventful past several months, as our production and demand for our products grew in Arizona," commented, Andrew Bowden, Item 9 Labs's Chief Executive Officer. "While most companies have been negatively impacted by the global COVID-19 pandemic, we have been more fortunate than most due to the fact that our cannabis products remain in high demand in Arizona."

Bowden, continued, "We expect revenues to continue to grow as the trends are positive month over month. At the same time, we have been able to lower costs since March 2020 and expect to see margins increase over the next several months. As we focus on increasing revenue, reducing expenses and performing more efficiently, our operating expenses as a percentage of revenue decreased from 108% to 57% for the three months ended June 30, 2020. We believe this ratio will continue to decrease going forward as our expectation is that revenues will continue to grow at a higher rate than operating expenses as we have our sights on turning EBITDA profitable."

Bowden concluded, "In addition to continued growth in Arizona, we are extremely excited about our expansion to Nevada and our pending acquisition of ONE Cannabis Group and its global dispensary franchise strategy. Our team is poised to execute on this expansion and believes it will add significant value to our shareholders. I couldn't be more personally excited about our future and believe we are well-positioned for future success."

Growth Initiatives

Arizona

Item 9 Labs currently offers more than 300 products that are grouped in the following categories: flower, concentrates, distillates, and hardware. The Company's product offerings will continue to grow as it develops new products to meet the needs of the end-users. Its products are available to consumers through more than 60 licensed dispensaries in Arizona.

The Company has expanded its Arizona facility and increased its production in the nine months ended June 30, 2020 to meet increased demand for its products.

Nevada

Item 9 Labs acquired cultivation, processing and production licenses in Nevada in early 2020, to go along with its Pahrump, Nevada land acquisition in 2018 to establish its expansion into Nevada. As of June 30, 2020, the licenses have not been transferred to the Company as the transfer is awaiting Nevada regulatory approval.

ONE Cannabis Group

Items 9 Labs expects to close its acquisition of OCG, Inc. ("ONE Cannabis Group") near the Company's fiscal year end of September 30, 2020. ONE Cannabis Group is the parent company to the cannabis dispensary franchise Unity Rd. The merger was previously disclosed on a Form 8-K filed with the U.S. Securities and Exchange on March 2, 2020. The parties are currently in negotiations to finalize certain necessary amendments to the merger agreement and completing the condition precedents and compliance-related matters. The merger with ONE Cannabis Group greatly enhances the Company's business capabilities with its retail distribution. Its cannabis dispensary franchise Unity Rd. is a first in industry and nationally recognized true cannabis franchise.

Financial Results for the Three Months Ended June 30, 2020:

Revenue for the three months ended June 30, 2020 was $2.2 million, an increase of $0.7 million or 43%, compared to $1.5 million for the three months ended June 30, 2019. The revenue increase was primarily due to an overall increase in monthly sales as production and demand for our products grew. Management anticipates revenues to continue to grow as the revenue trends are positive month over month.

Gross profit for the three months ended June 30, 2020 was $1.0 million, an increase of $0.2 million or 21%, compared to $0.8 million for the three months ended June 30, 2019. The resulting gross margin was 46% for the three months ended June 30, 2020, compared to 55% for the three months ended June 30, 2019. The decrease in gross margin was due to an increase in costs necessary to ramp up production to meet demand, as well as a pivot of its sales strategy for certain product lines, reducing margins in the short term. The Company has been able to lower costs since March 2020 and expects to see gross margins increase over the next several months.

Operating expenses for the three months ended June 30, 2020 were $1.3 million, a decrease of $0.4 million or 24%, compared to $1.7 million for the three months ended June 30, 2019. Operating expenses as a percentage of revenue decreased from 108% to 57% for the three months ended June 30, 2020, from the three months ended June 30, 2019. The decrease in operating expenses as a percentage of revenues for the three months ended June 30, 2020 was due to the Company's focus on increasing revenue, reducing expenses and performing more efficiently. Management believes this ratio will continue to decrease going forward as the expectation is that revenues will continue to grow at a higher rate than operating expenses.

Operating loss for the three months ended June 30, 2020 was $0.2 million, a decrease of $0.6 million, or 70%, compared to $0.8 million for the three months ended June 30, 2019.

Net loss for the three months ended June 30, 2020 was $1.6 million, an increase of $0.8 million, or 88%, compared to $0.9 million for the three months ended June 30, 2019. The net loss for the three months ended June 30, 2020 included $1.4 million of interest expense, as compared to minimal for the three months ended June 30, 2019. The resulting loss per share for the three months ended June 30, 2020 was ($0.03) per share, compared to ($0.01) per share for the three months ended June 30, 2019.

Adjusted EBITDA loss, after adding back non-cash operating expenses, depreciation and amortization, interest and stock-based compensation, for the three months ended June 30, 2020 was $0.04 million, a decrease of $0.4 million, or 91%, compared to $0.4 million for the three months ended June 30, 2019.

Financial Results for the Nine Months Ended June 30, 2020:

Revenue for the nine months ended June 30, 2020 was $5.6 million, an increase of $2.0 million or 54%, compared to $3.6 million for the nine months ended June 30, 2019.

Gross profit for the nine months ended June 30, 2020 was $2.1 million, an increase of $0.2 or 9%, compared to $1.9 million for the nine months ended June 30, 2019. The resulting gross margin was 37% for the nine months ended June 30, 2020, compared to 53% for the nine months ended June 30, 2019.

Operating expenses for the nine months ended June 30, 2020 was $4.4 million, an increase of $0.6 million or 15%, compared to $3.9 million for the nine months ended June 30, 2019. Operating expenses as a percentage of revenue decreased from 106% to 79% for the nine months ended June 30, 2020, from the nine months ended June 30, 2019.

Operating loss for the nine months ended June 30, 2020 was $2.3 million, an increase of $0.4 million, or 21%, compared to $1.9 million for the nine months ended June 30, 2019.

Net loss for the nine months ended June 30, 2020 was $5.2 million, an increase of $3.1 million, or 192%, compared to $2.1 million for the nine months ended June 30, 2019. The net loss for the nine months ended June 30, 2020 included $2.8 million of interest expense, as compared to minimal for the nine months ended June 30, 2019. The resulting loss per share for the nine months ended June 30, 2020 was ($0.08) per share, compared to ($0.03) per share for the nine months ended June 30, 2019.

Adjusted EBITDA loss, after adding back non-cash operating expenses, depreciation and amortization, interest and stock-based compensation, for the nine months ended June 30, 2020 was $1.2 million, a decrease of $0.1 million, or 4%, compared to $1.3 million for the nine months ended June 30, 2019.

Use of Non-GAAP Financial Measures

To supplement Item 9 Labs's financial statements presented on a GAAP basis, Item 9 Labs provides Adjusted EBITDA as a supplemental measure of its performance.

To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and decision-making surrounding pro forma operations, we supplement our consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, Adjusted EBITDA as a non-GAAP financial measures of earnings. Adjusted EBITDA represents EBITDA plus stock-based compensation and change in fair value of derivative liabilities. Our management uses Adjusted EBITDA, as financial measures to evaluate the profitability and efficiency of our business model. We use these non-GAAP financial measures to access the strength of the underlying operations of our business. These adjustments, and the non-GAAP financial measures that are derived from them, provide supplemental information to analyze our operations between periods and over time. We find this especially useful when reviewing pro forma results of operations, which include large non-cash amortizations of intangible assets from acquisitions and stock-based compensation. Investors should consider our non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

About Item 9 Labs Corp.

Item 9 Labs Corp. (OTCQB:INLB) is a vertically integrated multi-state cannabis operator headquartered in Arizona. The Company creates best-in-class products and canna-business solutions designed to help people become the best versions of themselves. With an award-winning CPG brand and nationally recognized application team, Item 9 Labs improves the cannabis experience while providing transparency, consistency, and well-being for those relying on them. For additional information, please visit: item9labscorp.com.

Media Contact:
Item 9 Labs
Jayne Levy, Director of Communications
Email: Jayne@unityrd.com

Investor Contact:
Hayden IR
Brett Mass, Managing Partner
Phone: (646) 536-7331
Email: INLB@haydenir.com

SOURCE: Item 9 Labs Corp.

ReleaseID: 601958

LOS ANGELES, CA / ACCESSWIRE / August 17, 2020 / Sanwire Corporation, ("Sanwire" or the "Company") (OTC PINK:SNWR), a diversified company focused on the entertainment industry, is pleased to announce its second quarter financial performance for its subsidiary Intercept Music, Inc. ("Intercept") and Art is War Record label ("AIW Records").

Per Sanwire's revenue guidance press release dated July 7, 2020, the Company is reporting better than expected results for the quarter ended June 30, 2020. Key highlights from second quarter compared to first quarter financial results are: Revenues increased by over 325% and Gross Profit increased by approximately 200%. All figures are unaudited and based on consolidated basis.

Sanwire's second quarter revenues encompass one whole quarter for Intercept (April-June 2020) and approximately three weeks of AIW Records June 9-30, 2020. Sanwire acquired Intercept on March 5, 2020 and AIW Records on June 9, 2020.

Management Comments

Tod Turner, President of Intercept, and Chris Whitcomb, CEO of Sanwire, commented, "Our financial performance for the first six months of 2020 validates our business plan. Despite domestic and international economic slowdown, we continue to experience increased demands for our products and services, especially Intercept PLUS, our label services program."

"Moving forward, we anticipate continued growth in third quarter of 2020, both in terms of increased revenues and business activities. We are adding new services on a regular basis and expanding existing services. The management team is committed to execute its vision to rapidly expand growth from existing markets and penetrate new ones."

Year-to-Date Milestones

· Acquisition of Intercept Music: Sanwire's foundational acquisition. This acquisition firmly entrenched Sanwire in the music distribution and marketing industry.

· Development of Intercept PLUS, artist label services program: Vastly expanded service offerings to include many of those services offered by a full-service label, including distribution, marketing/promotion, retail stores and more.

· Acquisition of Art is War record label: The acquisition of the label provided a strong base for the Intercept PLUS program with many artists ready to join.

· Addition of Mr. Jim Urie to Intercept's board of directors. Mr. Urie is the former president and chief executive officer of Universal Music Group Distribution Group. Called one of the "music industry distribution giants" by Billboard Magazine, Mr. Urie has had a career-long focus on maximizing profitability for music distribution, across all outlets and formats.

· Added physical music distribution through partnerships with Amplified Distribution (www.AmplifiedDistribution.com) and Super D (www.sdcd.com) that collectively provide distribution channels with major retailers including Amazon, Amazon International, Tower Japan, Barnes & Noble, BarnesNoble.com, and many others.

· Agreement with UK based company to expand service offerings and reach new markets.

· Addition of several brand ambassadors across several genres of music to expand our reach and influence nationally.

About Intercept Music, Inc.

Intercept Music, Inc. is an entertainment technology company dedicated to helping independent artists effectively distribute, market, and monetize their music. Sold through a Software as a Service (Saas) model, Intercept's online platform delivers an unsurpassed combination of marketing, promotion, and distribution to hundreds of stores worldwide and every major streaming service, including Apple Music, Google Music, Pandora and Spotify. Intercept's options include full-service, concierge-style support and even one-on-one coaching from award-winning music industry professionals. Intercept focuses exclusively on the independent music market, which is estimated at 12 million artists, and is the fastest-growing sector of the music industry. For more information, visit interceptmusic.com.

About Sanwire Corporation

Sanwire Corporation (OTC PINK:SNWR), a diversified company with a focus on the entertainment industry, has been involved in aggregating technologies for a number of years. We look for opportunities in fragmented markets, where technology can be applied to consolidate services into a single platform of delivery. Our current focus is advanced entertainment technologies. For more information, visit sanwirecorporation.com.

For further inquiries, contact ir@sanwirecorporation.com, casper.casparian@interceptmusic.com, or (424) 835-0833.

Safe Harbor Statement: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Act of 1934, as amended. All statements regarding our expected future financial positions, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the OTC Markets, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Sanwire Corporation

ReleaseID: 601960

Company Secures Financing From Clickstream Corporation to Expand Operations

LAS VEGAS, NV / ACCESSWIRE / August 17, 2020 / GoooGreen, Inc. (OTC PINK:GOOO) announces it has acquired VegasWINNERS Inc., a Nevada corporation which provides sports fans, sports betting enthusiasts, the highest quality analysis, research, data, guidance and professional advice, from celebrity Las Vegas sports gaming consultant, oddsmaker and businessman Wayne Allyn Root, and a team of some of the world's leading sports handicapping experts. The VegasWINNERS Inc. business model capitalizes on two hot business trends – the explosion of online gaming and the legalization of sports gambling.

According to Grandview Research, the global online gambling market size was valued at USD 53.7 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2020 to 2027. The high internet penetration and increasing use of mobile phones among individuals for playing online games from their homes and public places are driving the market. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

The Covid-19 pandemic has also added to the attractiveness of online gambling – introducing bettors to a new way of gambling from the safety of their home, office or mobile device, without entering a casino or sports stadium, or having to touch paper money.

Wagering on sports, including but not limited to the NFL, NBA, NHL, MLB, UFC, PGA, Soccer and NASCAR, as well as college sports (primarily football and basketball) are national pastimes for millions of sports enthusiasts. Historically, betting on sports was only legal in the State of Nevada and/or bets between friends, and those willing to bet illegally. In 2018, the United States Supreme Court decision allowing States to legalize sports betting has changed everything, creating tremendous opportunity. Twenty-two states plus Washington DC. have already legalized wagering on sports and, all but five states have legislation pending to allow it.

Terms of the deal included Clickstream Corp. (OTC Pink:CLIS) providing a $350,000 Secured Loan to GOOO for GOOO to acquire 96.5% of VegasWINNERS, Inc. and in return, CLIS purchased an option to acquire 14,901,200 of the current outstanding 17,842,925 shares of GOOO common stock for $175,000.

Frank Magliochetti, CEO of Clickstream, stated, "We've known of Wayne for years and believe VegasWINNERS will dramatically and positively impact the sports gaming industry. We are incredibly pleased to be able to help GoooGreen take VegasWINNERS to the next level and see this as a tremendous opportunity for Clickstream."

Tom Terwilliger, CEO of GoooGreen, Inc. stated "I believe this acquisition is strategic, especially during these times when life has gone online – viral. VegasWINNERS provides a needed portal for sports fans and bettors to stay connected and to invest in the games they're watching and the teams they love."

Wayne Allyn Root, CEO of VegasWINNERS stated, "What VegasWINNERS does is simple. Now that sports gaming has been legalized in over twenty states, there are millions of new sports gamblers. We supply the winning picks and research that these sports gamblers need. We intend to build a world-class database of sports gamblers, a database that should quickly prove valuable to casinos, sportsbooks and public gaming companies."

ABOUT GOOOGREEN, INC.

GoooGreen, Inc. (OTC Pink:GOOO) through its operating subsidiary VegasWINNERS, Inc. is engaged in the business of sports gambling research, data, advice, analysis and predictions utilizing all available media, advertising formats and its database of users. Revenues are expected to accelerate due to the explosion of sports handicapping arising from the 2018 Supreme Court decision that States have the right to approve sports gambling and the resulting State by State rapid approval of sports gambling. For more information, please visit VegasWINNERS website at www.vegaswinners.com as well as on Twitter at https://twitter.com/vegaswinnersinc.

ABOUT CLICKSTREAM CORPORATION

ClickStream Corporation OTC Pink:CLIS) business operations are focused on the development and implementation of WinQuikTM, a free to play synchronized mobile app and digital gaming platform. The platform is designed to enable WinQuikTM users to have fun, interact and compete against each other in order to win real money and prizes. WinQuikTM is currently in production with shows featuring Joshua Dobbs, Jordan Andino, Brian Baldinger, Howie Schwab, Amber Theoharis, and Mykel Hawke. Subject matter includes sports, sports movies, survival, food/culinary, the Bible and outer space. Game are set up dynamically with multiple non-live game shows throughout the day and once-a-day live game show. As a free-mium platform, ClickStream is in the process of monetizing the platform with corporate sponsors and advertisers. For more information please visit Clickstream's websites at www.clickstream.technology or www.WinQuik.com as well as on Twitter at https://twitter.com/ClickstreamC and https://twitter.com/search?q=winquik&src=typed_query.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR MORE INFORMATION, PLEASE CONTACT:

Adam Handelsman
SpecOps Communications
adam@specopscomm.com
O: (512) 363-0594
C: (646) 413-9401

SOURCE: GoooGREEN, INC.

ReleaseID: 601946

PMTA Initial Submission Is On Schedule and On Budget for the End of August

COSTA MESA, CA / ACCESSWIRE / August 17, 2020 / Charlie's Holdings, Inc. (OTC PINK:CHUC) ("Charlie's" or the "Company"), an industry leader in both the premium, nicotine-only, e-cigarette space and the hemp-derived, CBD wellness space, announced today the Company's financial results for the second quarter ended June 30, 2020.

Key Highlights for Q2 2020

Increased sales mix to distributors
Increased participation from distributors and retailers in volume incentive programs
Added margin from direct-to-consumer e-commerce sales of CBD products
Stabilized manufacturing costs

Premarket Tobacco Application ("PMTA")

Initial submission is on schedule and on budget for the end of August
Nearly $5 million spent over two years to prepare submission
Partnership with Blackbriar Regulatory Services utilizing numerous contract research organizations to analyze, compile, and publish necessary data
Submission to include scientific data and analysis along with clinical studies
Initial data finds no red flags to report

Management adopted a 15% reduction in pay for May and June 2020 and reduced personnel across several departments which resulted in approximately $170,000 of savings during the quarter ended June 30, 2020.

Management Commentary

"While we continue to experience industry headwinds from the nationwide vaping concerns and the uncertainty brought on from the global COVID-19 pandemic, we have taken the necessary steps to stabilize our manufacturing costs and reduce our operating expenses," stated Brandon Stump, Chief Executive Officer of Charlie's.

Stump, continued, "we remain focused on differentiating ourselves by being an early mover with our preparation for the submission of our PMTA. While the deadline to the Food and Drug Administration ("FDA") has been pushed back to September 9, 2020, we continue to compile more data and remain on track for our submission by the end of August, thanks to our partnership with Blackbriar Regulatory Services. In fact, we recently received minimal comments on our early data submission. We strongly believe our commitment to maintaining the highest standards of regulatory compliance, is a huge differentiating factor for our Company."

Stump, concluded, "we feel that the nicotine based flavored vaping products will continue to be a significant growth opportunity, once all the rightful regulatory changes have been made. We will continue with our plan to obtain marketing authorization for certain of our products through the submission of a PMTA. We expect the total cost associated with our preparation and submission of these PMTAs will total nearly $5.0 million spent over the past two years. In addition, we are evaluating the potential returns associated with obtaining marketing authorization for our other nicotine based vaping products after the September 2020 deadline. We feel that a significant amount of our competitors will not have the resources and/or expertise to complete the extensive and costly PMTA process and that once complete, we will be able to benefit from being one of only a select group of companies operating in the flavored nicotine product space. Finally, we believe the strength of our initial PMTA submission will create opportunity for additional SKUs to be taken through FDA approval. Whether it is through yet another robust PMTA submission or proving substantial equivalence, we look forward to taking additional products through FDA approval."

Financial Results for the Three Months Ended June 30, 2020

Revenue for the three months ended June 30, 2020 was $4,163,000, a decrease of $2,656,000, or 39%, compared to $6,819,000 for the three months ended June 30, 2019. The decrease was due to a $2,064,000 decrease in our nicotine-based product sales and a $571,000 decrease in sales of our CBD wellness products.

Gross profit for the three months ended June 30, 2020 was $2,431,000, a decrease of $1,542,000, or 39%, compared to $3,973,000 for the three months ended June 30, 2019. The resulting gross margin was 58.4% for the three months ended June 30, 2020, compared to 58.3% for the three months ended June 30, 2019.

General and administrative expense for the three months ended June 30, 2020 was $2,428,000, a decrease of $3,946,000, or 62%, compared to $6,374,000 for the three months ended June 30, 2019. This decrease is comprised of approximately $4,400,000 of non-cash, stock-based compensation, employee bonus and other transaction costs related to the share exchange expensed in the quarter ended June 30, 2019, offset by an increase of approximately $500,000 in various other general and administrative expenses during the quarter ended June 30, 2020. The decrease in transaction related costs includes $2,600,000 in additional non-cash, stock-based compensation, $1,600,000 of employee bonuses and $150,000 of other expenses incurred as a result of our share exchange in 2019. Payroll, insurance and bad debt expenses experienced the most significant year over year change during the quarter ended June 30, 2020 and accounted for approximately $435,000 of the $500,000 increase in other general and administrative expenses.

Sales and marketing expenses for the three months ended June 30, 2020 was $353,000, a decrease of $457,000, or 56%, compared to $810,000 for the three months ended June 30, 2019. The decrease was primarily due to lower commissions paid for reduced sales and curtailed spending on several marketing programs due to uncertainty in the global economy.

Research and development expense for the three months ended June 30, 2020 was $408,000, an increase of $408,000, compared to $0 for the three months ended June 30, 2019. The increase was primarily due to incurring costs associated with our PMTA registrations.

Operating loss for the three months ended June 30, 2020 was $758,000, a decrease of $2,453,000, or 78%, compared to $3,211,000 for the three months ended June 30, 2019.

Net loss for the three months ended June 30, 2020 was $644,000, a decrease of $2,389,000, or 79%, compared to $3,033,000 for the three months ended June 30, 2019.

Financial Results for the Six Months Ended June 30, 2020

Revenue for the six months ended June 30, 2020 was $8,568,000, a decrease of $4,898,000, or 36%, compared to $13,466,000 for the six months ended June 30, 2019. The decrease was due to a $5,184,000 decrease in our nicotine-based product sales, offset an increase in sales from our CBD wellness products business of $306,000.

Gross profit for the six months ended June 30, 2020 was $4,873,000, a decrease of $2,997,000, or 38%, compared to $7,870,000 for the six months ended June 30, 2019. The resulting gross margin was 56.9% for the six months ended June 30, 2020, compared to 58.4% for the six months ended June 30, 2019.

General and administrative expense for the six months ended June 30, 2020 was $6,427,000, a decrease of $602,000, or 9%, compared to $7,029,000 for the six months ended June 30, 2019. This decrease is comprised of approximately $2,500,000 of non-cash, stock-based compensation, employee bonus and other transaction costs related to the share exchange expensed in the six months ended June 30, 2019, offset by an increase of approximately $1,900,000 in various other general and administrative expenses during the six months ended June 30, 2020. The decrease in transaction related costs includes $741,000 in additional non-cash, stock-based compensation, $1,600,000 of employee bonuses and $150,000 of other expenses incurred as a result of our share exchange in 2019. Payroll, insurance and bad debt expenses experienced the most significant year over year change during the six months ended June 30, 2020 and accounted for approximately $1,300,000 of the $1,900,000 increase in other general and administrative expenses.

Sales and marketing expenses for the six months ended June 30, 2020 was $924,000, a decrease of $653,000, or 41%, compared to $1,577,000 for the six months ended June 30, 2019. The decrease was primarily due to lower commissions paid for reduced sales and curtailed spending on several marketing programs due to uncertainty in the global economy.

Research and development expense for the six months ended June 30, 2020 was $2,631,000, an increase of $2,631,000, compared to $0 for the six months ended June 30, 2019. The increase was primarily due to incurring costs associated with our PMTA registrations.

Operating loss for the six months ended June 30, 2020 was $5,109,000, an increase of $4,373,000, or 594%, compared to $736,000 for the six months ended June 30, 2019.

Net loss for the six months ended June 30, 2020 was $4,560,000, an increase of $4,002,000, or 717%, compared to $558,000 for the six months ended June 30, 2019.

About Charlie's Holdings, Inc.

Charlie's Holdings, Inc. (OTC Pink: CHUC) is an industry leader in both the premium, nicotine-only, e-cigarette space and the hemp-derived, CBD wellness space through its subsidiary companies Charlie's Chalk Dust, LLC and Don Polly, LLC. Charlie's Chalk Dust produces high quality vapor products currently distributed in more than over 90 countries around the world. Charlie's Chalk Dust has developed an extensive portfolio of brand styles, flavor profiles and innovative product formats. Launched in June of 2019, Don Polly, LLC formulates innovative hemp-derived CBD wellness products. Don Polly's high quality CBD products derive from single-strain-sourced hemp extract and high purity CBD isolate crystals.

For additional information, please visit our corporate website at: CharliesHoldings.com and our branded online websites: CharliesChalkDust.com and EnjoyPachamama.com.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company's overall business, existing and anticipated markets and expectations regarding future sales and expenses. Words such as "expect," "anticipate," "should," "believe," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "could," "intend," variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company's ability to successful increase sales and enter new markets; the Company's ability to manufacture and produce product for its customers; the Company's ability to formulate new products; the acceptance of existing and future products; the complexity, expense and time associated with compliance with government rules and regulations affecting nicotine and products containing cannabidiol; litigation risks from the use of the Company's products; risks of government regulations; the impact of competitive products; and the Company's ability to maintain and enhance its brand, as well as other risk factors included in the Company's most recent quarterly report on Form 10-K, Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Investors Contact:

IR@charliesholdings.com
p949-418-4020

SOURCE: Charlie's Holdings, Inc.

ReleaseID: 601951